Dialysis company’s stock falls again after Novo Nordisk said Ozempic was successful in treating kidney failure in a trial
Dialysis company DaVita Inc. issued a statement on Thursday in response to the news Wednesday from Novo Nordisk that its Ozempic treatment for Type 2 diabetes delayed the progression of chronic kidney disease in a trial.
However, he said that while it’s almost impossible to draw conclusions from the study, whose results have yet to be released, “based on the inclusion criteria for study participants, we believe there may be limited application of the FLOW study findings to the overall CKD patient population.” The full results, which Novo Nordisk said will be released in the first half of 2024, will identify which endpoint was met. If it confirms previous findings that glucagon-like peptide-1s, or GLP-1s, reduce cardiovascular mortality, it would be positive. About six times more CKD patients die of cardiovascular disease than develop the need for a kidney replacement.Ozempic and Wegovy have also been approved as weight-loss drugs and have become highly popular in the U.S.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon, Amgen and moreThese are some of the stocks posting the largest moves midday.
Read more »
Stocks making the biggest moves midday: Novo Nordisk, DaVita, Exxon Mobil, Amgen and moreThese are some of the stocks posting the largest moves midday.
Read more »
Stock movers: Novo Nordisk, Fresenius Medical Care, DaVita, Thor IndustriesNovo Nordisk, Thor Industries, Silk Road Medical, Fresenius Medical Care, and DaVita all showed stock price movement in pre-market trading
Read more »
Stock movers: DaVita, Exxon Mobil, Ozempic drug parent Novo NordiskExxon Mobil stock falls after the oil giant announces a $59.5 billion all-stock deal to buy Pioneer Natural Resources
Read more »
Dialysis-company stocks slide after Ozempic trial's success in treating kidney diseaseDaVita’s stock was down 16%, while Baxter and Intuitive Surgical were down 9% and 6%
Read more »
Voxx International, Walgreens rise; Exxon Mobil, DaVita fall, Wednesday, 10/11/2023Stocks that are trading heavily or have substantial price changes on Wednesday:
Read more »